facebook twitter linkedin
  • images/stories/slider.png
  • images/stories/slider2.png
  • images/stories/slider3.png
  • images/stories/slider4.png

NEWS RELEASES

  • Selvita shows strong revenue growth in the first quarter of 2015

    Krakow, 12 May 2015 - Selvita, the largest drug discovery company in Central and Eastern Europe, generated a net profit of PLN 1.3 MM in the first quarter of 2015, which marks 119% increase as compared to Q1 2014. EBITDA reached value of PLN 1.9 MM,…

    Read More...

  • Selvita establishes its UK subsidiary in Cambridge

    Cambridge, UK - Krakow, Poland - 05 May 2015 - Selvita (WSE: SLV), a global drug discovery company with offices in the US and Poland, is opening its first office in the United Kingdom. The office is based in Cambridge, considered to be one of the mos…

    Read More...

  • Selvita initiates IND-enabling Studies for its first-in-class PIM/FLT3 inhibitor

    Krakow, 31 March 2015 - Selvita (WSE:SLV), the largest drug discovery company in Central and Eastern Europe, announced today that it is commencing IND-enabling studies for SEL24 project, the company’s first oncology drug candidate. &n SEL24 is a nov…

    Read More...